Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 25;7(5):514-521.
doi: 10.1093/nop/npaa022. eCollection 2020 Oct.

Antidepressant drug use in glioblastoma patients: an epidemiological view

Dorothee Gramatzki  1   2 , James Louis Rogers  1 , Marian Christoph Neidert  2 , Caroline Hertler  1   3 , Emilie Le Rhun  1 , Patrick Roth  1 , Michael Weller  1
Affiliations

Antidepressant drug use in glioblastoma patients: an epidemiological view

Dorothee Gramatzki et al. Neurooncol Pract. .

Abstract

Background: Antidepressant drugs have shown antitumor activity in preclinical glioblastoma studies. Antidepressant drug use, as well as its association with survival, in glioblastoma patients has not been well characterized on a population level.

Methods: Patient characteristics, including the frequency of antidepressant drug use, were assessed in a glioblastoma cohort diagnosed in a 10-year time frame between 2005 and 2014 in the Canton of Zurich, Switzerland. Cox proportional hazards regression models were applied for multivariate analysis. Kaplan-Meier survival curves were used to estimate overall survival (OS) data and the log-rank test was performed for comparisons.

Results: A total of 404 patients with isocitrate dehydrogenase wild-type glioblastoma were included in this study. Sixty-five patients (16.1%) took antidepressant drugs at some point during the disease course. Patients were most commonly prescribed selective serotonin reuptake inhibitors at any time (N = 46, 70.8%). Nineteen patients (29.2%) were on antidepressant drugs at the time of their tumor diagnosis. No differences were observed in OS between those patients who had taken antidepressants at some point in their disease course and those who had not (P = .356). These data were confirmed in a multivariate analysis including age, Karnofsky Performance Scale (KPS), sex, extent of resection, O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status, and first-line treatment as cofounders (P = .315). Also, there was no association of use of drugs modulating voltage-dependent potassium channels (citalopram; escitalopram) with survival (P = .639).

Conclusions: This signal-seeking study does not support the hypothesis that antidepressants have antitumor efficacy in glioblastoma on a population level.

Keywords: antidepressants; depression; epidemiology; glioblastoma; survival.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Antidepressant Drugs and Survival A, Kaplan-Meier curves of overall survival are shown for patients who took antidepressant drugs (black) or who had not taken antidepressant drugs (gray) at any time during the course of the disease. B, The same Kaplan-Meier survival curves are shown stratified for patients who took drugs modulating voltage-dependent potassium channels (blue; citalopram, escitalopram) and those who had not taken any other antidepressant drugs (green). The log-rank test was used for comparison.
See this image and copyright information in PMC

References

    1. Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol. 2019; 21(suppl 5):v1–v100. - PMC - PubMed
    1. Weller M, Le Rhun E, Preusser M, Tonn JC. Roth P.. How we treat glioblastoma. ESMO Open. 2019;4(suppl 2):e000520. - PMC - PubMed
    1. Weller M, van den Bent M, Tonn JC, et al. ; European Association for Neuro-Oncology (EANO) Task Force on Gliomas European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18(6):e315–e329. - PubMed
    1. Gramatzki D, Dehler S, Rushing EJ, et al. Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer. 2016;122(14):2206–2215. - PubMed
    1. Gramatzki D, Roth P, Rushing EJ, et al. Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. Ann Oncol. 2018;29(6):1431–1436. - PubMed